An open-label, single-arm phase I dose escalation study was conducted in Australia to evaluate the efficacy of YH002 alone in patients with advanced solid tumors. The preliminary results from this study, completed in June 2022, demonstrated that YH002 was both safe and effective for treating advanced solid tumors.
We have received the IND approvals from the NMPA and the U.S. FDA for Phase I clinical trials of YH002 as a single agent in China and the U.S..
This multicenter, open-label phase I dose escalation study aimed to assess the safety, tolerability, and pharmacokinetics of YH002 in combination with YH001 (a CTLA-4 monoclonal antibody) among patients with advanced solid tumors. The study was conducted simultaneously in Australia and China. In July 2022, enrollment for three dose groups of YH002 combined with YH001 was completed in Australia for the YH002004 trial.
OX40 is a type I transmembrane glycoprotein belonging to the TNFRSF family and plays an essential role as a costimulator of T cell response by enhancing TCR signaling after engagement. It promotes proliferation and survival while also releasing effector cytokines that prevent T-cell tolerance formation. Additionally, activation of OX40 inhibits the production and secretion of inhibitory cytokines such as IL-10 and TGF-b by Treg cells while contributing significantly to memory T cell formation.
There are currently no marketed OX40 drugs.
Oct. 18, 2022 | Eucure Biopharma, a Subsidiary of Biocytogen Pharmaceuticals, Licenses OX40 Antibody (YH002) and Multiple Active Ingredients to Syncromune for the Development and Commercialization of Intratumoral Immunotherapy